Similarly, anti-PD-1 antibodies were shown to significantly reverse the exosome-mediated blockade of T-cell activation in glioblastoma (145), suggesting that these anti-PD-1 antibodies compete with exoPD-L1 to bind to PD-1 on T cells (131). Here, PDCD1 is linked to glioblastoma.